Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Trials

Potential treatments for macular degeneration must successfully complete human clinical trials before seeking approval by the U.S. Food and Drug Administration.

Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.

We are currently conducting a Phase 2a study of AVA-101 in wet AMD. Learn More.


Join our mailing list and receive updated information as it becomes available:

Avalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock

July 31, 2014

MENLO PARK, Calif., July 31, 2014 -- Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Avalanche. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AAVL".

Read More

Read All Avalanche News